Onkologie. 2008:2(4):239-245

RADIOTHERAPY PROSTATE CANCER

Pavol Dubinský
Klinika rádioterapie a onkológie VOÚ, a.s., Košice

Radiotherapy, radical prostatectomy, watchful waiting and hormonal therapy are the basic treatment modalities for prostate cancer. External beam radiotherapy and brachytherapy alone or in combination with other means of treatment represents curative option for non-metastatic disease. Conformal radiotherapy improves toxicity profile by reduction of volumes of irradiated normal tissues. Conformal radio­therapy planning is based on extensive clinical research and is well understood and standardized. There are some unresolved questions and controversies in prostate cancer radiotherapy. The most predominant are as follows: long term treatment outcomes with prostatectomy versus modern radiotherapy, the clinical value of intensity modulated radiotherapy and target localization, dose escalation in various prognostic groups, optimal fractionation in presumed low α/β ratio, volumes to be irradiated, mainly the role of pelvic irradiation, timing and duration of androgen deprivation therapy in various risk groups, indication of postoperative and salvage radiotherapy and relative efficacy of brachytherapy.

Keywords: Key words: prostate cancer, radiotherapy, androgen deprivation.

Published: December 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dubinský P. RADIOTHERAPY PROSTATE CANCER. Onkologie. 2008;2(4):239-245.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-51. Go to original source... Go to PubMed...
    2. Prostate cancer. In National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version version 1. 2008. Jenkinstown, PA: National comprehensive cancer network, May 2008. Available from: http://www.nccn.org/professionals/physician_gls/default.asp.
    3. Senior adult oncology. In National comprehensive cancer network clinical practice guidelines in oncology, version version 1. 2008. Jenkinstown, PA: National comprehensive cancer network, May 2008. Available from: http://www. nccn.org/ professionals/physician_gls/default.asp.
    4. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 32: 8165-8169. Go to original source... Go to PubMed...
    5. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-106. Go to original source... Go to PubMed...
    6. 167 PR06 Collaborators. Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial. BJU Int 2004; 94: 1400-1401. Go to PubMed...
    7. Wallace K, Fleshner N, Basiuk J, et al. Impact of a multidisciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the Surgical Prostatectomy Versus Interstitial radiation Intervention Trial. J Clin Oncol 2006; 24: 4158-4162. Go to original source... Go to PubMed...
    8. Mills N, Donovan J, Smith M, et al. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials 2003; 24: 272-282. Go to original source... Go to PubMed...
    9. Bracarda S, de Conbelli O, Greco C, et al. Cancer of the prostate. Crit Rev Oncol Haematol 2005; 56: 379-396. Go to original source... Go to PubMed...
    10. D´Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. Go to original source... Go to PubMed...
    11. Fletcher SG, Mills SE, Smolkin ME, et al. Case matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Onclo Biol Phys 2006; 66: 1092-1099. Go to original source... Go to PubMed...
    12. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy >= 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33. Go to original source... Go to PubMed...
    13. Speight JL, Roach III M. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005; 23: 8176-8185. Go to original source... Go to PubMed...
    14. Clinical guidelines. In Americal urological association May 2008. Available from: www.auanet.org.
    15. Frank SJ, Pisters LL, Davis J, et al. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer, J Urol, 2007; 177: 2151-2156. Go to original source... Go to PubMed...
    16. Diefenbach MA, Mohamed NE. Regret of treatment decision and its association with disease-specific quality of life following prostate cancer treatment, Cancer Invest 2007; 25: 449-457. Go to original source... Go to PubMed...
    17. Purdy JA. Three-dimensional conformal radiation therapy: physics, treatment planning and clinical aspects. In: Perez CA, Brady LW: Principles and practice of radiation oncology. Lippincott 2004; 28-13.
    18. Boehmer D, Maingon P, Poortmans, et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 2006; 79: 259-269. Go to original source... Go to PubMed...
    19. Hoogeman MS, van Herk M, de Bois J, et al. Strategies to reduce the systematic errordue to tumour and rectum motion in radiotherapy of prostate cancer. Radiother Oncol 2005; 74: 177-185. Go to original source... Go to PubMed...
    20. Kupelian PA, Langen KM, Willoghby TR, et al. Image-guided radiotherapy for localized prostate cancer: treating a moving target: Sem Rad Oncol 2008; 18: 58-66. Go to original source... Go to PubMed...
    21. Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol 2008; 86: 142-147. Go to original source... Go to PubMed...
    22. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose excalation using conformal radiotherapy in prostate cancer: PSA control and side effects. B J Cancer 2005; 92: 488-498. Go to original source... Go to PubMed...
    23. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005; 23: 6132-6138. Go to original source... Go to PubMed...
    24. Peeters STH, Heemsbergen WD, Koper PC, et al. Dose response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-1996. Go to original source... Go to PubMed...
    25. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-1105. Go to original source... Go to PubMed...
    26. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199. Go to original source... Go to PubMed...
    27. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation usin photons alone. Int j Radiat Oncol Biol Phys 1995; 32: 3-12. Go to original source... Go to PubMed...
    28. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-1239. Go to original source... Go to PubMed...
    29. Dearnaley DP, Sydes M, Graham JD, et al. Escalated versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial, Lancet Oncol 2007; 8: 459-460. Go to original source... Go to PubMed...
    30. Speight JL, Roach III M. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005; 23: 8176-8185. Go to original source... Go to PubMed...
    31. van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker based three-dimensional fusion of CT with dynamic contrast enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006; 65: 291-303. Go to original source... Go to PubMed...
    32. van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006; 64: 5343-5345. Go to original source... Go to PubMed...
    33. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005; 23: 6132-6138. Go to original source... Go to PubMed...
    34. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: update results of a phase III randomized trial. Int j Radiat Oncol Biol Phys 2006; 66: 1072-1083. Go to original source... Go to PubMed...
    35. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose excalation trial. Int J Radiat Oncol Biol Phys 2006; 64: 158-226. Go to original source... Go to PubMed...
    36. Livsey JE, Cowan RA, Wylie JP. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003, 57: 1254-1259. Go to original source... Go to PubMed...
    37. Kupelian PA, Willoughby TR, Reddy CA. Hypofractionated intensity modulated radiotherapy (70 Gy at 2,5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys 2007; 63: 1424-1430. Go to original source... Go to PubMed...
    38. Soete G, Arcangeli S, De Meerleer G. Phase II study of a four week hypofractionated external beem radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006; 80: 78-81. Go to original source... Go to PubMed...
    39. Madsen BL, His RA, Pham HT. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33,4 Gy in five fractions for localized disease: First clinical trial results. Int Radiat Oncol. Biol. Phys 2007; 67: 1099-1105. Go to original source... Go to PubMed...
    40. Dubinský P, Belánová K, Matula M. Akútna toxicita hypofrakcionovanej rádioterapie karcinómu prostaty. Brněnské onkologické dny, abstr. 2008.
    41. Dirix P, Haustermans K, Junius S, et al. The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol 2006; 79: 1-14. Go to original source... Go to PubMed...
    42. Roach M 3rd, DeSilvio C, Lawton CA, et al. Phase III trial comparing whole-pelvis versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-1911. Go to original source... Go to PubMed...
    43. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25: 5366-5373. Go to original source... Go to PubMed...
    44. Lawton C, Desilvio M, Roach M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-655. Go to original source... Go to PubMed...
    45. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-1290. Go to original source... Go to PubMed...
    46. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patents with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103-106. Go to original source... Go to PubMed...
    47. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252. Go to original source... Go to PubMed...
    48. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-3978. Go to original source... Go to PubMed...
    49. Roach M 3rd, DeSilvio M, Thomas CR, et al. Whole-pelvis,, ,mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006; 66: 647-653. Go to original source... Go to PubMed...
    50. See WA, Tyrrell CJ. Casodex trade mark Early Prostate Cancer Trialists´ Group. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006; 132: 7-13. Go to original source... Go to PubMed...
    51. Tyrrel CJ, Payne H, See WA, et al. Bicalutamide (´Casodex´) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005; 76: 4-10. Go to original source... Go to PubMed...
    52. D´Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827. Go to original source... Go to PubMed...
    53. Morris MM, Dallow KC, Zietman AL, et al. Adjuvant and salvage irradiation following radical prostatectomyfor prostate cancer. Int J Radiat. Oncol. Biol. Phys 1997; 38: 731-736. Go to original source... Go to PubMed...
    54. Pacholke HD, Wajsman Z, Algood CB, et al. Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology 2004; 64: 982-986. Go to original source... Go to PubMed...
    55. Syndikus I, Pickles T, Kostashuk E, et al. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol 1996; 155: 1983-1986. Go to original source... Go to PubMed...
    56. Stein A, deKernion JB, Dorey F, et al. Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology 1992; 39: 59-62. Go to original source... Go to PubMed...
    57. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EARTC trial 22911). Lancet 2005; 366: 572-578. Go to original source... Go to PubMed...
    58. Thompson Jr IM, Tangen CM, Paradelo, J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335. Go to original source... Go to PubMed...
    59. Weigel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus wait and see (WS)in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95) J Clin Oncol 2005 (abstr 4513), 23: 381. Go to original source...
    60. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004, 296: 2329-2335. Go to original source... Go to PubMed...
    61. Macdonald OK, Schild SA, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy J Urol 2003; 170: 1833-1837. Go to original source... Go to PubMed...
    62. Valicenti RK, Gomella LG, Ismail M, et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42: 501-506. Go to original source... Go to PubMed...
    63. Galalae RM, Martinez A Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int Radiat Oncol Biol Phys 2004; 58: 1048-1055. Go to original source... Go to PubMed...
    64. Nickers P, Coppens L, de leval J, et al. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol 2006; 79: 329-334. Go to original source... Go to PubMed...
    65. Roach jr M, Shinohara K, Weinberg V, et al. Contemporary results of permanent prostate seed implantation (PPI) versus conformal proton beam radiotherapy (CPBRT) to 79 GyE. J Clin Oncol 2005; 23: 412 s. abstr 4639. Go to original source...
    66. Ash D, Flynn A, Batterman J, et al. ESTRO/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315-321. Go to original source... Go to PubMed...
    67. Kovacs G, Potter R, Loch T, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer. Radiother Oncol 2005; 74: 137-148. Go to original source... Go to PubMed...
    68. Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10. Go to original source... Go to PubMed...
    69. Dearnaley DL, Sydes MR, Langley RE, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 1999; 353: 267-272. Go to original source... Go to PubMed...
    70. Karlsdottir A, Johannessen DC, Muren LP, et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 2004; 71: 43-53. Go to original source... Go to PubMed...
    71. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-46. Go to original source... Go to PubMed...
    72. Pavy JJ, Denekamp J, Letschert J, et al. EORTC late effects working group late effects toxicity scoring: the SOMA scale. Radiat Oncol 1995; 35: 11-15. Go to original source... Go to PubMed...
    73. Common terminology criteria for adverse events v. 3.0 (CTCAE) May 2008. Available from https://ctep.cancer.gov.
    74. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose excalation using conformal radiotherapy in prostate cancer: PSA control and side effects. B J Cancer 2005; 92: 488 4-498. Go to original source... Go to PubMed...
    75. Zelefsky MJ, Fuks Z, Leibel SA. Intensity modulated radiation therapy for prostate cancer. Semin Radiat Oncol 2002; 3: 229-237. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.